Itoga Masamichi, Ishioka Yoshiko, Makiguchi Tomonori, Tanaka Hisashi, Taima Kageaki, Saito Norihiro, Tomita Hirofumi, Tasaka Sadatomo
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan; Department of Clinical Laboratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan; Division of Infection Control and Prevention, Hirosaki University Hospital, 53 Honcho, Hirosaki, 036-8563, Japan.
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.
Immunol Lett. 2024 Feb;265:16-22. doi: 10.1016/j.imlet.2023.12.001. Epub 2023 Dec 22.
G protein-coupled estrogen receptor (GPER) is an estrogen receptor located on the plasma membrane. We previously reported that the administration of G-1, a GPER-specific agonist, suppressed development of acute ovalbumin (OVA)-induced asthma in a mouse model. Herein, we evaluate the involvement of GPER in a mouse model of chronic OVA asthma.
G-1 or saline was administered subcutaneously to BALB/c mice with chronic OVA asthma, and pathological and immunological evaluation was performed. In addition, Foxp3-expressing CD4-positive T-cells in the spleen and ILC2 in the lungs were measured using flow cytometry.
We observed a significant decrease in the number of inflammatory cells in the bronchoalveolar lavage fluid (BALF) in the G-1 treated group. In the airways, inflammatory cell accumulation, Th2 cytokines (IL-4, IL-5, IL-13, and eotaxin) and epithelial cytokine TSLP were suppressed, while in the BALF, anti-inflammatory cytokines (IL-10 and TGF-β) were increased. Furthermore, in splenic mononuclear cells, Foxp3-expressing CD4-positive T-cells were increased in the G-1 group, whereas treatment with G-1 did not change the percentage of ILC2 in the lungs.
G-1 administration suppressed allergic airway inflammation in mice with chronic OVA asthma. GPER may be a potential therapeutic target for chronic allergic asthma.
G蛋白偶联雌激素受体(GPER)是一种位于质膜上的雌激素受体。我们之前报道,给予GPER特异性激动剂G-1可抑制小鼠模型中急性卵清蛋白(OVA)诱导的哮喘发展。在此,我们评估GPER在慢性OVA哮喘小鼠模型中的作用。
对患有慢性OVA哮喘的BALB/c小鼠皮下注射G-1或生理盐水,并进行病理和免疫学评估。此外,使用流式细胞术检测脾脏中表达Foxp3的CD4阳性T细胞和肺中的2型固有淋巴细胞(ILC2)。
我们观察到G-1治疗组支气管肺泡灌洗液(BALF)中炎症细胞数量显著减少。在气道中,炎症细胞积聚、Th2细胞因子(IL-4、IL-5、IL-13和嗜酸性粒细胞趋化因子)和上皮细胞因子TSLP受到抑制,而在BALF中,抗炎细胞因子(IL-10和转化生长因子-β)增加。此外,在脾单核细胞中,G-1组中表达Foxp3的CD4阳性T细胞增加,而G-1治疗并未改变肺中ILC2的百分比。
给予G-1可抑制慢性OVA哮喘小鼠的过敏性气道炎症。GPER可能是慢性过敏性哮喘的潜在治疗靶点。